http://www.pharmaasia.comPharmaAsia - Clinical Trialsen-USCopyright 2012 Ten Alps Communications Asia. All rights reserved.Thu, 24 May 2012 12:46:49 +0800http://www.pharmaasia.com/article/acm-global-central-laboratory-establishes-mumbai-based-subsidiary/9393ACM Global Central Lab has advanced its hybrid central lab model in Mumbai with an operational facility dedicated to manage clinical trials testing in India and provide study support throughout Asia Pacific.http://www.pharmaasia.com/article/acm-global-central-laboratory-establishes-mumbai-based-subsidiary/9393Tue, 15 May 2012 00:00:00 +0800http://www.pharmaasia.com/article/telormedix-s-tmx-101-exhibits-high-safety-in-phase-i-ii-for-non-muscle-invasive-bladder-cancer/9386Telormedix announced that it has successfully completed the safety portion of a Phase I/II trial for TMX-101.http://www.pharmaasia.com/article/telormedix-s-tmx-101-exhibits-high-safety-in-phase-i-ii-for-non-muscle-invasive-bladder-cancer/9386Fri, 4 May 2012 00:00:00 +0800http://www.pharmaasia.com/article/aslan-pharmaceuticals-selects-pharmanet-i3-as-partner-for-oncology-development/9383Aslan Pharmaceuticals has selected PharmaNet/i3 as a partner supporting the development of their oncology portfolio in Asia.http://www.pharmaasia.com/article/aslan-pharmaceuticals-selects-pharmanet-i3-as-partner-for-oncology-development/9383Wed, 2 May 2012 00:00:00 +0800http://www.pharmaasia.com/article/incivek-is-well-tolerated-with-commonly-used-atripla-and-reyataz-based-hiv-treatment-regimens/9382Phase 2 study of INCIVEK combination regimen shows 74 percent of people co-infected with hepatitis C, HIV had undetectable hepatitis C virus 12 weeks after treatment ended.http://www.pharmaasia.com/article/incivek-is-well-tolerated-with-commonly-used-atripla-and-reyataz-based-hiv-treatment-regimens/9382Mon, 30 Apr 2012 00:00:00 +0800http://www.pharmaasia.com/article/us-fda-grants-priority-review-to-bayer-s-xarelto/9366Bayer, together with its cooperation partner, Janssen Research & Development, announced that the US FDA has granted priority review designation to the supplemental New Drug Application (sNDA) filed on December 29, 2011 for the oral anticoagulant Xarelto.http://www.pharmaasia.com/article/us-fda-grants-priority-review-to-bayer-s-xarelto/9366Mon, 9 Apr 2012 00:00:00 +0800http://www.pharmaasia.com/article/salix-initiates-target-3-phase-3-study/9361Salix initiates Target 3 phase 3 study to assess repeat treatment efficacy and safety of Rifaximin 550MG TID in subjects with irritable bowel syndrome with diarrheahttp://www.pharmaasia.com/article/salix-initiates-target-3-phase-3-study/9361Fri, 6 Apr 2012 00:00:00 +0800http://www.pharmaasia.com/article/icon-acquires-pricespective/9362The acquisition strengthens ICON’s expertise in value based pricing and market access.http://www.pharmaasia.com/article/icon-acquires-pricespective/9362Thu, 5 Apr 2012 00:00:00 +0800http://www.pharmaasia.com/article/major-it-trends-shaping-life-sciences-in-2012/9351Three IT trends will shape the life sciences in 2012, according to an analysis by SAFE-BioPharma Association. They are the expanded use of standards-based interoperable digital identities, cloud computing in clinical trials, and the use of electronic trial master files for clinical trial management.http://www.pharmaasia.com/article/major-it-trends-shaping-life-sciences-in-2012/9351Fri, 23 Mar 2012 00:00:00 +0800http://www.pharmaasia.com/article/two-fold-adds-multi-groups-capability-to-qualoupe-lims-solution/9354Two Fold Software has added a versatile multi-groups capability to its Qualoupe LIMS (Laboratory Information Management System) solution. The software enhancement offers complete data management flexibility for organizations and companies that not only have multiple sites but also include multiple laboratories within each site.http://www.pharmaasia.com/article/two-fold-adds-multi-groups-capability-to-qualoupe-lims-solution/9354Wed, 21 Mar 2012 00:00:00 +0800http://www.pharmaasia.com/article/greenphire-merge-healthcare-form-partnership-to-integrate-clinical-payment-and-edc-platforms/9349Greenphire has formed an exclusive partnership with the clinical trials division of Merge Healthcare to offer integrated functionality between Merge’s EDC technology and Greenphire’s eClinicalGPS site and vendor payment management technology.http://www.pharmaasia.com/article/greenphire-merge-healthcare-form-partnership-to-integrate-clinical-payment-and-edc-platforms/9349Thu, 15 Mar 2012 00:00:00 +0800